A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants | MicrobiomeTrials← Back to trialsNCT06663436
A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2024-11-13Est. Completion: 2025-10-21
Enrollment target: 200 participants Locations- GSK Investigational Site, Kericho, Kenya
Other microbiome trials you might be interested in
Painful Menstruation
This study will test whether a standardized ginger extract improves menstrual pain and related symptoms compared with pl…
Multiple LocationsEst. completion Aug 2027
Fabry Disease
The aim of this randomized controlled study is to evaluate the effects of a six-week low-fermentable oligosaccharides, d…
Istanbul, Turkey (Türkiye)Est. completion Jan 30, 2027
Recurrent C. Difficile (rCDI)
Ulcerative Colitis (UC)
Metabolic Syndrome (MetS)
The gut microbiota plays a key role in immunity and metabolism and contributes to diseases such as recurrent C. difficil…
Rome, ItalyEst. completion Jan 19, 2029